Prostate News Archive
05-Mar-2008
GTX Shares Fall on Study Concern (AP via Yahoo! Finance)
Shares of biotechnology company GTX Inc. stumbled Monday on concerns on the risks involved with a late-stage study of the company's prostate cancer drug Acapodene. The Risk Of Renal Impairment In Hormone-Refractory Prostate Cancer Patients With Bone Metastases Treated With ... (Medical News Today)
UroToday.com- Nearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment according to a report by Dr. Oh and colleagues in the online version of Cancer.ZA is an intravenous bisphosphonate given to decrease skeletal related events in CaP patients with bone metastases. [click link for full article] Prostate cancer worries women (Daily Telegraph)
WOMEN are initially more distressed by prostate cancer than their male partners who are diagnosed with the disease, a study has found. For Men, a Saving Surgery: Twenty-Five Years Ago, Patrick C. Walsh Devised a Prostate-Cancer Operation That Allowed ... (RedNova)
By Marie McCullough, The Philadelphia Inquirer Apr. 30--In 1982, the surgical cure for prostate cancer was considered worse than the disease. Removing the prostate meant life-threatening bleeding, guaranteed impotence, and a 1 in 4 chance of incontinence.
Back to Prostate News Archive
